SCHEMBL1056384

SCHEMBL1056384

CCOB(OCC)OCC.[NaH]

nearest known ligand 0.30

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL50777 0.96 ALDH1A1 (0.32) ALDH1A1
SCHEMBL27913833 0.96 ALDH1A1 (0.32) ALDH1A1
Water SCHEMBL28116863 0.92 ALDH1A1 (0.30) ALDH1A1
SCHEMBL3041911 0.92 ALDH1A1 (0.30) ALDH1A1
Ammonia Solution, Strong SCHEMBL9328292 0.92 ALDH1A1 (0.30) ALDH1A1
Fluoride SCHEMBL23120036 0.92 ALDH1A1 (0.30) ALDH1A1
SCHEMBL6154385 0.92 ALDH1A1 (0.30) ALDH1A1
Lithium Ion SCHEMBL10846050 0.88
SCHEMBL10843317 0.88
Dimethylamine SCHEMBL3618358 0.85

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119080798-A Preparation method of 4,5,6, 7-tetrahydrothiophene [3,2-c ] pyridine hydrochloride 杭州永太生物医药有限公司 2024-12-06 CN claimed
CN-111018700-B Oxocyclo [8] arene derivatives and preparation method thereof 清华大学 2023-03-31 CN claimed
CN-115073534-A Synthetic method of emamectin benzoate 吴晓明 2022-09-20 CN claimed
CN-113943330-A Sugar-containing structure compound, preparation method, pharmaceutical composition and application thereof 中国科学院上海药物研究所 2022-01-18 CN claimed
CN-109734643-B Method for synthesizing pyrroline compound by catalyzing amino alcohol and enol with iron 陕西师范大学 2021-05-14 CN claimed
CN-111018700-A Oxocyclo [8] arene derivatives and preparation method thereof 清华大学 2020-04-17 CN claimed
US-20090176847-A1 Dicyclooctane Derivatives, Preparation Processes and Medical Uses Thereof SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) 2009-07-09 US claimed
EP-2006284-A1 DICYCLOOCTANE DERIVATES, PREPARATION PROCESSES AND MEDICAL USES THEREOF Shanghai Hengrui Pharmaceutical Co. Ltd. (CN) 2008-12-24 EP claimed
EP-0262061-B1 PROCESS FOR STABILIZING CHLORINATION MIXTURES OF PHENOL AND/OR CHLOROPHENOLS RHONE-POULENC CHIMIE (FR) 1993-02-24 EP claimed
US-4853153-A USING REDUCING AGENT AND CHLORINATED CYCLIC KETONE RHONE-POULENC CHIMIE (FR) 1989-08-01 US claimed
US-4578482-A Process for preparing prostacyclins TEIJIN LIMITED (JP) 1986-03-25 US claimed
EP-0113577-A1 Process for preparing prostacyclins TEIJIN LIMITED (JP) 1984-07-18 EP claimed
CN-119504751-A Bifunctional chimeric heterocyclic compound for targeting and degrading androgen receptor and application thereof 海创药业股份有限公司 2025-02-25 CN disclosed
CN-113683611-B Novel RET inhibitors, pharmaceutical compositions thereof and uses thereof 广东东阳光药业股份有限公司 2025-02-11 CN disclosed
CN-119156383-A Selective KRAS G12C inhibitors and uses thereof 1200药业有限责任公司 2024-12-17 CN disclosed
CN-119080798-A Preparation method of 4,5,6, 7-tetrahydrothiophene [3,2-c ] pyridine hydrochloride 杭州永太生物医药有限公司 2024-12-06 CN disclosed
US-3983158-A PROSTAGLANDINS THE UPJOHN COMPANY (US) 1976-09-28 US disclosed
US-3983157-A PROSTAGLANDINS THE UPJOHN COMPANY (US) 1976-09-28 US disclosed
US-3980694-A ANTIULCER, ANTIAGGLOMERANTS, INCREASE OF NASAL PATENCY, LABOR INDUCEMENT, WOUND HEALINGPROSTAGLANDINS THE UPJOHN COMPANY (US) 1976-09-14 US disclosed
US-3931289-A PROSTAGLANDINS THE UPJOHN COMPANY (US) 1976-01-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090176847-A1 Dicyclooctane Derivatives, Preparation Processes and Medical Uses Thereof DPP4, DPP7, DPP8 ALDH1A1 1142/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.